Get Your Personalized Supplement StackSupplement Stack Quiz

Adhatoda

Also known as: Justicia adhatoda, Adhatoda zeylanica, Malabar nut, Vasaka, Adhatoda vasica

Overview

Adhatoda, primarily Adhatoda vasica (also known as Justicia adhatoda or Adhatoda zeylanica), is a medicinal plant indigenous to South Asia, widely utilized in traditional Ayurvedic and Unani medicine. It is recognized for its rich content of alkaloids, particularly vasicine and vasicinone, which are believed to be responsible for its therapeutic effects. Historically, Adhatoda has been a cornerstone in treating various respiratory ailments, including bronchitis and asthma, due to its purported bronchodilatory and expectorant properties. More recently, research has explored its anti-inflammatory, anti-diabetic, and potential adjunctive roles in conditions like COVID-19. While preclinical studies and some small clinical trials support its traditional uses and emerging applications, the overall research maturity is moderate, with a need for more extensive, high-quality human trials to fully establish its efficacy and safety.

Benefits

Adhatoda offers several evidence-based benefits, primarily in respiratory health and metabolic regulation. A clinical trial involving mild COVID-19 patients demonstrated that an extract of Adhatoda vasica, combined with Tinospora cordifolia, led to faster viral clearance and reduced markers of hypoxia, inflammation, and thrombosis without reported adverse effects. This suggests its potential as an adjunct therapy for respiratory conditions, particularly those involving inflammation and hypoxia. The strength of this evidence is moderate, based on an open-label RCT. Furthermore, Adhatoda exhibits significant anti-diabetic effects, as shown in in vitro and in vivo studies. It has been found to inhibit α-amylase activity, thereby reducing carbohydrate digestion and glucose absorption, and has successfully lowered blood glucose levels in diabetic rat models. This effect appears dose-dependent and is linked to its alkaloid content, particularly vasicine. The evidence for anti-diabetic effects is strong at the preclinical level, but human clinical trials are needed. Additionally, an ethanolic extract of Adhatoda zeylanica has shown nephroprotective effects, attenuating kidney damage in streptozotocin-induced diabetic rats, indicating potential for renal protection in diabetic conditions.

How it works

Adhatoda exerts its therapeutic effects through multiple mechanisms, primarily attributed to its alkaloid constituents like vasicine and vasicinone. In respiratory conditions, it is believed to act as a bronchodilator and expectorant, potentially by relaxing smooth muscles and promoting mucolytic activity, though specific pathways require further elucidation. Its anti-inflammatory and anti-hypoxic properties, particularly relevant in conditions like COVID-19, involve the modulation of hypoxia-inducible factor-1 alpha (HIF-1α) and the reduction of inflammatory markers such as ferritin, VEGF, and coagulation factors. For its anti-diabetic effects, Adhatoda primarily functions by inhibiting the α-amylase enzyme. This inhibition reduces the breakdown of complex carbohydrates into simpler sugars, thereby decreasing glucose absorption from the gut and consequently lowering post-prandial blood glucose levels. Molecular docking studies support the binding of its alkaloids to the active sites of these enzymes.

Side effects

The safety profile of Adhatoda appears favorable, particularly in short-term use, though comprehensive human safety data are still emerging. A clinical trial involving COVID-19 patients reported no adverse effects, and animal studies have shown no mortality or acute toxicity at doses up to 2000 mg/kg, indicating a high safety margin. Common side effects in humans are not well-documented, and traditional use suggests good tolerability. However, due to its observed effects on coagulation and glucose metabolism, there is a theoretical potential for interactions with anticoagulant medications (blood thinners) and antidiabetic drugs. Specific clinical data on these interactions are currently lacking, so caution is advised for individuals on such medications. Contraindications are not definitively established due to insufficient data. However, given the lack of specific safety data, Adhatoda is generally not recommended for use during pregnancy and lactation. Individuals with pre-existing medical conditions or those taking other medications should consult a healthcare professional before using Adhatoda supplements.

Dosage

Specific standardized dosing guidelines for Adhatoda in humans are not yet firmly established, as clinical trials often use proprietary extracts with varying concentrations of active compounds. In the clinical trial for mild COVID-19, a combination extract was used, but precise dosages were not detailed in the summary. Preclinical animal studies have shown significant glucose-lowering effects in diabetic rat models at doses that are fractions of the LD50 (e.g., around 500 mg/kg), indicating efficacy at relatively safe levels. The form of Adhatoda commonly studied includes ethanolic extracts, with the alkaloid content, particularly vasicine, being critical for its activity. While bioavailability data are limited, the bioactive alkaloids are considered the primary active constituents. Due to the variability in extract standardization and the limited human clinical data, it is crucial to follow product-specific recommendations from reputable manufacturers or consult with a healthcare professional for appropriate dosing, especially when targeting specific health conditions. Upper limits and safety thresholds for long-term human use are not yet well-defined.

FAQs

Is Adhatoda safe for COVID-19?

Preliminary clinical data suggest Adhatoda may be safe and potentially beneficial as an adjunct therapy for mild COVID-19, showing faster viral clearance and reduced inflammation markers. However, more extensive research is needed.

Can it be used for diabetes?

Preclinical evidence strongly supports Adhatoda's anti-diabetic potential by inhibiting glucose absorption and lowering blood sugar. However, human randomized controlled trials are currently lacking to confirm these effects clinically.

How fast do effects appear?

In the COVID-19 trial, quicker viral clearance was observed within days. Anti-diabetic effects in animal models typically manifest over several weeks of consistent use.

Are there known side effects?

No significant adverse effects were reported in a clinical trial for COVID-19, and animal studies indicate a high safety margin. However, comprehensive human safety data, especially for long-term use, are still limited.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC10696694/ – This open-label, three-arm RCT investigated a polyherbal formulation including Adhatoda vasica in mild COVID-19 patients. It found that the formulation led to faster viral clearance and reduced markers of hypoxia, inflammation, and thrombosis without adverse effects, suggesting its potential as an adjunct therapy.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11365037/ – This in vitro and in silico study demonstrated the dose-dependent α-amylase inhibitory activity of Adhatoda vasica ethanolic extract. Molecular docking analysis supported the binding of its alkaloids to the enzyme's active sites, providing a mechanistic basis for its anti-diabetic potential.
https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0040-1722801.pdf – This animal RCT on streptozotocin-induced diabetic rats showed that an ethanolic extract of Adhatoda zeylanica significantly reduced blood glucose levels and improved renal parameters. The study also reported no toxicity at high doses, indicating its safety and nephroprotective effects in a diabetic model.
https://journals.sagepub.com/doi/abs/10.1177/27536130241270621 – This in vitro study focused on the α-amylase inhibitory activity of purified vasicine from Adhatoda vasica. It determined a potent IC50 value for vasicine, highlighting it as a key anti-diabetic constituent and supporting the plant's traditional use for glycemic control.